Lafutidine

Bezeichnung:Lafutidine

CAS-Nr118288-08-7

Englisch Name:Lafutidine

CBNumberCB4297653

SummenformelC22H29N3O4S

Molgewicht431.55

MOL-Datei118288-08-7.mol

Lafutidine physikalisch-chemischer Eigenschaften

Schmelzpunkt	92.7-94.9°
Siedepunkt	704.2±60.0 °C(Predicted)
Dichte	1.252±0.06 g/cm3(Predicted)
storage temp.	Sealed in dry,Store in freezer, under -20°C
Wasserlöslichkeit	Insoluble in water
Löslichkeit	DMF:5.0(Max Conc. mg/mL);11.59(Max Conc. mM) DMSO:48.67(Max Conc. mg/mL);112.77(Max Conc. mM) DMSO:PBS (pH 7.2) (1:10):0.09(Max Conc. mg/mL);0.21(Max Conc. mM) Ethanol:9.0(Max Conc. mg/mL);20.86(Max Conc. mM)
Aggregatzustand	powder to crystal
pka	13.13±0.46(Predicted)
Farbe	White to Orange to Green
CAS Datenbank	118288-08-7(CAS DataBase Reference)

Sicherheit

S-Sätze:	24/25
HS Code	29349990

Gefahreninformationscode (GHS)

Lafutidine Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung
Lafutidine was launched in Japan for the treatment of gastritis, reflux oesophagitis and peptic ulcers. It can be prepared in eight steps from 4-(2-tetrahydropyranyloxy)-2(Z)-butenl- ol. Lafutidine is a potent and longer-acting H₂ antagonist compared to other marketed compounds of its class such as cimetidine and famotidine. In contrast to other commercially available H₂ antagonists, lafutidine also exerts a gastroprotective action probably via capsaicin-sensitive afferent nerves. It was clinically effective in the treatment of nonsteroidal antiinflammatory drug-induced ulcer in patients refractory to existing antiulcer agents.
Beschreibung
Lafutidine is a histamine H₂ receptor antagonist with gastroprotective activity. It inhibits histamine-induced cAMP production in CHO cells expressing human histamine H₂ receptors when used at a concentration of 10 nM. Intragastric administration of lafutidine (3, 10, and 30 mg/kg) reduces hemorrhagic esophageal lesion size and gastric acid secretion in a rat model of pyloric ligation-induced reflux esophagitis. It prevents 5-fluorouracil-induced intestinal mucositis, diarrhea, and body weight loss in wild-type, but not Trpv1^-/- or sensory deafferented, mice when administered at doses ranging from 3 to 30 mg/kg. Lafutidine (10 mg/kg) also reduces indomethacin-induced antral ulcer size in wild-type, but not chemically-deafferented, rats.
Originator
Fujirebio (Japan)
Verwenden
Lafutidine, a newly developed histamine H(2)-receptor antagonist, inhibits gastric acid secretion
Verwenden
(Z)-2-((Furan-2-ylmethyl)sulfinyl)-n-(4-((3-(piperidin-1-ylmethyl)pyridin-2-yl)oxy)but-2-en-1-yl)acetamide is a Histaminic H2 receptor antagonists in ulcer disease. Also, it is a model compound used to investigate the binding mechanism between antiulcer drugs and human serum albumin (HSA).
Verwenden
Second generation histamine H2-receptor antagonist. Antiulcerative
Definition
ChEBI: Lafutidine is an organic molecular entity.
Trademarks
Stogar, Protecadin

Lafutidine Upstream-Materialien And Downstream Produkte

Lafutidine Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

118288-08-7, Lafutidine Verwandte Suche:

Send Inquriy